AVNS vs. ESTA, SMTI, ENOV, IOVA, RXRX, RDNT, PRCT, RCKT, EYE, and CINC
Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include Establishment Labs (ESTA), Sanara MedTech (SMTI), Enovis (ENOV), Iovance Biotherapeutics (IOVA), Recursion Pharmaceuticals (RXRX), RadNet (RDNT), PROCEPT BioRobotics (PRCT), Rocket Pharmaceuticals (RCKT), National Vision (EYE), and CinCor Pharma (CINC). These companies are all part of the "medical" sector.
Avanos Medical vs.
Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
In the previous week, Establishment Labs had 1 more articles in the media than Avanos Medical. MarketBeat recorded 5 mentions for Establishment Labs and 4 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.14 beat Establishment Labs' score of -0.38 indicating that Avanos Medical is being referred to more favorably in the news media.
Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
75.3% of Establishment Labs shares are owned by institutional investors. Comparatively, 92.1% of Avanos Medical shares are owned by institutional investors. 12.4% of Establishment Labs shares are owned by insiders. Comparatively, 2.1% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Avanos Medical has a net margin of 6.07% compared to Establishment Labs' net margin of -46.51%. Avanos Medical's return on equity of 6.13% beat Establishment Labs' return on equity.
Establishment Labs has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
Establishment Labs presently has a consensus price target of $100.86, indicating a potential upside of 42.15%. Avanos Medical has a consensus price target of $30.00, indicating a potential upside of 5.01%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe Establishment Labs is more favorable than Avanos Medical.
Establishment Labs received 24 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 60.71% of users gave Establishment Labs an outperform vote while only 56.52% of users gave Avanos Medical an outperform vote.
Summary
Establishment Labs and Avanos Medical tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avanos Medical Competitors List
